Follow the Innovent Biologics, Inc. share price and the full insider trade history of the company, a listed equity based in Hong Kong. Shares trade on the HK market, under the supervision of HKEX. Operating in the Health Care sector, Innovent Biologics, Inc. has recorded 16 reports. Market capitalisation: €156.6bn. The latest transaction was reported on 9 July 2026 (Sale). Among the most active insiders: Ede Ronald Hao Xi. The full history is free.
16
Insider Decl.
n/a
Thresholds
n/a
8 ops.
Buy Volume
€58m
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Innovent Biologics, Inc. Strong Buy (bullish), based on 25 analysts. Average price target: HK$117.45.
31Σ signal
Buys n/a€58m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,433 of 29,053 companies
56.9
score / 100
Value
51
Quality
63
FCF yld5.2%
Earn yld0.5%
EV/EBITDA·
ROE7.0%
Gross mgn87%
Net mgn6.2%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
986,000 shares@ HK$85.000.0067% mcap49.5% of flowShareXHKGHKEX:DA20260401E00593
16 of 16 declarations
About Innovent Biologics, Inc.
Innovent Biologics, Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of cancer and other diseases. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.